14th Pipeline Report
Each year, Pharmaceutical Executive reviews the highlights of the current drug pipeline. This year, the pipeline report looks at oncology, regenerative medicine, ophthalmology and neuroscience. In addition, some gene therapy examples are presented as they are setting the stage for this sector to explode. Discussions with analysts, investment firms, and biopharma executives, as well as a look at regulatory and Silicon Valley impacts, round out the science discussion.

Executive Profile
Ruud Dobber, Ph.D, President, AstraZeneca US and Executive Vice President, North America, is featured as our executive profile. Dobber has been overseeing North America and the US for a bit over a year, having previously served in similar executive capacities the EU, EMEA, and Asia Pacific. Dobber discusses the challenges associated with the US healthcare system, AstraZeneca’s excitement around its 2018 launches, and the business focus for the number 11 company on our Pharma 50 list.